It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Bile acid diarrhoea (BAD) is a common disorder resulting from increased loss of bile acids (BAs), overlapping irritable bowel syndrome with diarrhoea (IBS-D). The gut microbiota metabolises primary BAs to secondary BAs, with differing impacts on metabolism and homeostasis. The aim of this study was to profile the microbiome, metabolic products and bile acids in BAD. Patients with BAD diagnosed by SeHCAT testing, were compared with other IBS-D patients, and healthy controls. Faecal 16S ribosomal RNA gene analysis was undertaken. Faecal short chain fatty acid (SCFA) and urinary volatile organic compounds (VOCs) were measured. BAs were quantified in serum and faeces. Faecal bacterial diversity was significantly reduced in patients with BAD. Several taxa were enriched compared to IBS-D. SCFA amounts differed in BAD, controls and IBS-D, with significantly more propionate in BAD. Separation of VOC profiles was evident, but the greatest discrimination was between IBS-D and controls. Unconjugated and primary BA in serum and faeces were significantly higher in BAD. The faecal percentage primary BA was inversely related to SeHCAT. BAD produces dysbiosis, with metabolite differences, including VOC, SCFA and primary BAs when compared to IBS-D. These findings provide new mechanistic insights into the pathophysiology of BAD.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 University of Warwick, Warwick Medical School, Coventry, UK (GRID:grid.7372.1) (ISNI:0000 0000 8809 1613)
2 Sorbonne Paris Cité, Louis Mourier Hospital, DHU Unity APHP, and Inserm UMR 1149, Team BADO, UFR de Médecine Paris Diderot, Paris, France (GRID:grid.469994.f) (ISNI:0000 0004 1788 6194)
3 University of Warwick, Warwick Medical School, Coventry, UK (GRID:grid.7372.1) (ISNI:0000 0000 8809 1613); Quadram Institute Bioscience, Norwich, UK (GRID:grid.40368.39) (ISNI:0000 0000 9347 0159)
4 University of Warwick, School of Engineering, Coventry, UK (GRID:grid.7372.1) (ISNI:0000 0000 8809 1613)
5 University of Glasgow, School of Medicine, Glasgow, UK (GRID:grid.8756.c) (ISNI:0000 0001 2193 314X)
6 Imperial College London, and Imperial College Healthcare, Division of Digestive Diseases, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)
7 University of Warwick, Warwick Medical School, Coventry, UK (GRID:grid.7372.1) (ISNI:0000 0000 8809 1613); University Hospitals Coventry and Warwickshire, Division of Gastroenterology, Coventry, UK (GRID:grid.412570.5) (ISNI:0000 0004 0400 5079); Coventry University, Biological Sciences, Coventry, UK (GRID:grid.8096.7) (ISNI:0000000106754565)